Sign in
Taking people in United StatesPhase 2

Improving Therapeutic Learning for PTSD

Key facts

Who runs it
University of Wisconsin, Madison
Where
Austin and Madison, United StatesSee the 2 sites
Trial code
Status
Recruiting
Phase
Phase 2
People taking part
120 people, planned
Started
18 Feb 2021
Planned end
Dec 2023
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • L-DOPA
  • Placebo
Record updated
30 August 2023

Who can take part

Age
21 years to 50 years
Sex
Women only
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 29 criteriaShow less

Who can take part

  • Current diagnosis of PTSD where the index traumatic event includes physical or sexual assault
  • English speaking
  • Medically healthy

Who cannot take part

  • internal ferromagnetic objects (such as electronic devices, surgical implants, shrapnel, etc.)
  • use of Monoamine oxidase inhibitors (MAO-I) in past two weeks is exclusionary; Additional Exclusion Criteria at UT-Austin:
  • Electronic or magnetic implants, such as pacemakers, as these may stop working
  • Medications which may affect image quality (e.g., water pills)
  • Nonremovable dental implants, such as braces or upper permanent retainers, as these will distort the MRI images we collect (note: filings, crowns, and silver or gold teeth are OK)
  • major medical disorders (such as cancer)
  • psychotic disorders
  • neurocognitive disorders
  • developmental disorders
  • heart disease
  • hepatic impairment
  • peptic ulcer disease
  • prescription medications that may interact with L-DOPA will not be permitted during a predetermined wash-out period; Due to safety concerns, participants with these conditions will be ineligible to participate:
  • Major medical disorders (e.g., HIV, cancer)
  • Magnetic metallic implants (such as screws, pins, shrapnel remnants, aneurysm clips, artificial heart valves, inner ear (cochlear) implants, artificial joints, and vascular stents), as these may heat, pull, or twist in the strong magnetic field of the MRI scanner
  • A self-reported history of loss of consciousness (greater than 30 minutes)
  • Psychotic disorders (e.g., schizophrenia)
  • Any other condition that the investigator believes might put the participant at risk; Due to their effects on image quality, participants with the following MAY be ineligible to participate per Principal Investigator's judgment:
  • Any other condition, medication, or implant that the investigator believes would degrade image quality or render data unusable
  • pregnancy
  • breastfeeding
  • COPD
  • Claustrophobia, or the inability to lie still in a confined space
  • Permanent makeup or tattoos with metallic dyes
  • A positive pregnancy test (for females), since the effect of strong magnetic fields and L-Dopa on the developing fetus remains unknown and inconclusive. (all female participants of childbearing potential will have a pregnancy test on the day of the MRI scan. Participants who test positive would be notified of this positive result)
  • Physical disabilities that prohibit task performance (such as blindness or deafness)

The main criteria, as questions

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 21 and 50 years old?

Where in United States

  • University of TexasAustin, United StatesContact: Josh Cisler, PhD (principal investigator)Taking people
  • University of WisconsinMadison, United StatesContact: Rachel WilliamsNo longer taking part

About the trial

What the trial wants to find out

The proposed project seeks to demonstrate the engagement of post-exposure dopamine neurotransmission and downstream acute reorganization of dopaminergic resting-state neural networks as a means of increasing consolidation of extinction memories formed during analogue exposure therapy in adult women with PTSD. Participants will include 120 women aged 21-50 with a current diagnosis of PTSD related to physical or sexual assault, English speaking, and medically healthy. Participants will complete the stages of the study across 2-3 days, depending on participant need.

The 2 groups in the trial

  • 100 mg L-DOPATreatment being tested

    Complete a \~40 min fMRI scan with either hearing their trauma or neutral narrative, ingest a pill (placebo or 100mg L-DOPA) upon leaving the scanner and wait in a waiting room for \~45 minutes, then undergo a 7 min resting-state fMRI scan.Participants return \~24 hours later for Day 2 fMRI, in which they will complete a single \~40-minute fMRI scan while listening to either their trauma or neutral narrative.

    Treatment: L-DOPA

  • PlaceboPlacebo, for comparison

    Complete a \~40 min fMRI scan with either hearing their trauma or neutral narrative, ingest a pill (placebo or 100mg L-DOPA) upon leaving the scanner and wait in a waiting room for \~45 minutes, then undergo a 7 min resting-state fMRI scan.Participants return \~24 hours later for Day 2 fMRI, in which they will complete a single \~40-minute fMRI scan while listening to either their trauma or neutral narrative.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Criteria questions
Built from NCT04558112, who can take part
Publications
Record updated
30 August 2023